everolimus
everolimus: sourced relationships with 1 company · 50 clinical trials tracked · 3 FDA decisions.
everolimus evidence translation
What we can confirm
3 FDA records · 50 tracked trials
What it means
What to watch
Prepared research question
How could everolimus → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 5 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2009-03-30 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (50)showing 10 most recent
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Primary endpoint: Proportion of patients progression-free
A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster)
Primary endpoint: Best Overall Response Rate (BORR)
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Primary endpoint: Safety and adverse events (AEs).
Characterization of mTOR Inhibitor Pharmacokinetics and Pharmacodynamics in Older Adults .
Primary endpoint: Cmax for Sirolimus
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects
Primary endpoint: Pharmacokinetics (PK) of mTOR inhibitor in blood
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Primary endpoint: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas
Primary endpoint: Determination of the safety and technical feasibility of microdevice insertion/removal, as assessed by adverse events by CTCAE 5.0.
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors
Primary endpoint: To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)
Primary endpoint: Progression-free Survival (PFS)
Targeting mTOR With Everolimus and/or Physical Training for Preventing Postmenopausal Bone Loss and Accelerated Skeletal Aging: The RapaLoad Study
Primary endpoint: Procollagen type 1 N-terminal propeptide (P1NP)
FDA Decisions3 records
Frequently asked questions
Which companies have sourced relationships with everolimus?
everolimus has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve everolimus?
BioSniper tracks 50 clinical trials involving everolimus.
What is everolimus's latest FDA decision?
The most recent tracked FDA decision for everolimus is Approval, dated August 29, 2012.